| This sample attributes table contains sample IDs, body site where sample was collected, acquisition type, pre- or post FGFR2 inhibitor treatment, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, and name of the center which conducted sequencing. | Name of the center which conducted sequencing | phv00408888.v1.p1 |
| This sample attributes table contains sample IDs, body site where sample was collected, acquisition type, pre- or post FGFR2 inhibitor treatment, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, and name of the center which conducted sequencing. | Tumor status | phv00408885.v1.p1 |
| This sample attributes table contains sample IDs, body site where sample was collected, acquisition type, pre- or post FGFR2 inhibitor treatment, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, and name of the center which conducted sequencing. | Whether the tumor was collected as a biopsy or at autopsy | phv00408882.v1.p1 |
| This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. | Subject ID | phv00408875.v1.p1 |
| This subject phenotype table contains subject IDs, case control status of the subject for cholangiocarcinoma, and sex. | Subject ID | phv00408877.v1.p1 |
| The subject consent file includes subject IDs and consent information. | Consent group as determined by DAC | phv00408874.v1.p1 |
| This sample attributes table contains sample IDs, body site where sample was collected, acquisition type, pre- or post FGFR2 inhibitor treatment, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, and name of the center which conducted sequencing. | Primary tumor, metastasis, or transformed cell line | phv00408887.v1.p1 |
| This sample attributes table contains sample IDs, body site where sample was collected, acquisition type, pre- or post FGFR2 inhibitor treatment, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, and name of the center which conducted sequencing. | Sample ID | phv00408880.v1.p1 |
| This sample attributes table contains sample IDs, body site where sample was collected, acquisition type, pre- or post FGFR2 inhibitor treatment, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, and name of the center which conducted sequencing. | Whether the tumor is pre- or post-FGFR2 inhibitor treatment | phv00408883.v1.p1 |
| The subject consent file includes subject IDs and consent information. | Subject ID | phv00408873.v1.p1 |
| This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. | Sample ID | phv00408876.v1.p1 |
| This subject phenotype table contains subject IDs, case control status of the subject for cholangiocarcinoma, and sex. | Self-reported sex | phv00408879.v1.p1 |
| This sample attributes table contains sample IDs, body site where sample was collected, acquisition type, pre- or post FGFR2 inhibitor treatment, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, and name of the center which conducted sequencing. | Cell or tissue type or subtype of sample | phv00408886.v1.p1 |
| This subject phenotype table contains subject IDs, case control status of the subject for cholangiocarcinoma, and sex. | Case control status of the subject for cholangiocarcinoma | phv00408878.v1.p1 |
| This sample attributes table contains sample IDs, body site where sample was collected, acquisition type, pre- or post FGFR2 inhibitor treatment, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, and name of the center which conducted sequencing. | Body site where sample was collected | phv00408881.v1.p1 |
| This sample attributes table contains sample IDs, body site where sample was collected, acquisition type, pre- or post FGFR2 inhibitor treatment, analyte type, tumor status, histological type, primary tumor, metastasis, or transformed cell line, and name of the center which conducted sequencing. | Analyte Type | phv00408884.v1.p1 |